Serotonin syndrome: Case report and review of the literature

Connecticut Medicine

Volumn 61, Issue 11, 1997, Pages 717-721

  Weiner, Alan L ^a,b,c   Tilden Jr , Fred F ^b,c   McKay Jr , Charles A ^b,c  

^a Medical Toxicology   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROHEPTADINE; IMIPRAMINE; PAROXETINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DELIRIUM; DEPRESSION; DRUG WITHDRAWAL; FEMALE; FLUID THERAPY; HUMAN; MYOCLONUS; SEDATION; SEROTONIN SYNDROME; TACHYCARDIA; TREATMENT PLANNING;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DRUG SYNERGISM; DRUG TOXICITY; FEMALE; HUMANS; IMIPRAMINE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNDROME;

EID: 0030664031     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Sternbach HS: The serotonin syndrome. Am J Psych 1991; 148: 705-12.
2. Mills KC: Serotonin syndrome. Am Fam Physician 1995; 52: 1475-82.
3. Martin TG: Serotonin syndrome. Ann Emerg Med 1996; 28:520-6.
4. Bodner RA, Lynch TL, Lewis LA, et al: Serotonin Syndrome. Neurology 1995; 45:219-23.
5. Oates JA, Sjoerdsma A: Neurologic effects of tryptophan in patients receiving a monoamine oxidase Inhibitor. Neurology 1960; 10:1076-8.
6. Hodge JV, Oates SA, Sjoerdsma A: Reduction of the central effects of tryptophan by a decarboxylase inhibitor. Clin Pharmacol Ther 1964; 5:149-55.
7. Gerson SC, Baldessarini RJ: Motor effects of serotonin in the central nervous system. Life Sci 1980; 27:1435-51.
8. Kaminski CA, Robbins MS, Weibley RE: Sertralineintoxication in a child. Ann Emerg Med 1994; 23:1371-4.
9. Sporer KA: The serotonin syndrome: Implicated drugs, pathophysiology and management. Drug Safety 1995; 13:94-104.
10. Neuvonen PJ: Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses (letter). Lancet 1993; 342:1419.
11. Green AR, Kelly PH: Evidence concerning involvement of 5-HT in locomotor activity produced by amphetamine or tranylcypromine-1-dopa. Br J Pharmacol 1996; 57:141-47.
12. Yamada J, Sugimoto Y, Horisaka K: The evidence for the involvement of the 5-HT1A receptor in serotonin syndrome in mice. Japanese J Pharmacol 1989; 51:421-5.
13. Lucki I, Nobler MS, Frazer A: Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther 1984; 228:133-9.
14. Coplan JD, Gorman JM: Detectable levels of fluoxetine metabolites after discontinuation: An unexplained serotonin syndrome (letter). Am J Psych 1993; 150:837.
15. Pato MT, Murphy DL, Devane CL: Sustained plasma concentrations of fluoxetine and norfluoxetine four and eight weeks after fluoxetine discontinuation. J Cin Pharmacol 1991; 11:224-5.
16. Kolecki P: Venlafexine induced serotonin syndrome occurring after abstinence from phenelzine for more than four weeks (letter). Clin Tox 1997; 35:211.
17. Browne BA, Linter SA: Monoamine oxidase inhibitors and narcotic analgesics. Br J Psych 1987; 151:210-2.
18. Brown TM, Skop BP: Pathophysiology and management of the serotonin syndrome. Ann Pharmacotherapy 1996; 20:527-33.
19. Brubacher JR: Treating the serotonin syndrome: Antidote orsupport? (letter) Clin Tox 1997; 35:213-4.
20. Lappin RI, Auchincloss EL: Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med 1994; 231:1021-2.
21. Sandyk RA: L-dopa induced serotonin syndrome in a Parkinsons patient on bromocriptine. J Clin Psychopharm 1986; 6:194-5.